Combining FLT3L with an agent to promote maturation of DCs (poly I:C) was essential to promote an effective anti-PD-L1 mediated immune response.30 These examples were all done in extracranial tumor models, but in the intracerebral SB28 model, the addition of polyIC:LC or CD40 agonist did not substantially improve FLT3L therapy. Here, FLT3LG is linked to neoplasm.